Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 8/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.68 |
| ▸ | KDR | P35968 | 4/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 3/20 | 0.53 |
| ▸ | ITK | Q08881 | 3/20 | 0.53 |
| ▸ | JAK3 | P52333 | 3/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | TDP2 | O95551 | 1/20 | 0.52 |
| ▸ | PLCG1 | P19174 | 3/20 | 0.51 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24150548 | 1.00 | TEK (0.68) | TEKEPHB4KDREGFRPDGFRB | |
| SCHEMBL24150642 | 0.80 | JAK3 (0.48) | TEKEPHB4KDRBTKITK | |
| SCHEMBL30190538 | 0.80 | JAK3 (0.48) | TEKEPHB4KDRBTKITK | |
| SCHEMBL23721287 | 0.79 | SLC2A1 (0.55) | EGFR | |
| SCHEMBL24151412 | 0.78 | BTK (0.57) | EGFRBTKITKJAK3JAK1 | |
| SCHEMBL30190863 | 0.78 | BTK (0.57) | EGFRBTKITKJAK3JAK1 | |
| SCHEMBL24150530 | 0.78 | MAP4K4 (0.60) | EGFRBTKJAK3JAK1 | |
| SCHEMBL24150139 | 0.78 | GAK (0.52) | EGFRBTKITKJAK3JAK1 | |
| SCHEMBL24150540 | 0.77 | JAK3 (0.60) | EGFRBTKITKJAK3JAK1 | |
| SCHEMBL30190551 | 0.77 | JAK3 (0.60) | EGFRBTKITKJAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | TEK 4357/4885EPHB4 2721/4885KDR 3104/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | TEK 4357/4885EPHB4 2721/4885KDR 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.